Abstract 316
Background
A series of randomized controlled trials (RCTs) comparing S-1 with 5-FU or capecitabine in mono or combined therapy for colorectal cancer (CRC). The meta-analysis aims to compare the efficacy and safety profile of S-1-based versus non- S-1-based chemotherapy as first-line treatment in CRC.
Methods
Relevant RCTs were obtained from PubMed, Embase, Ovid databases and the Cochrane library from database set up to May 2018. The included studies were selected according to eligibility criteria. The study design, participant characteristics, interventions, and outcomes were abstracted after the assessment of methodological quality of the trials. All data were analyzed by Review Manager 5.3.
Results
10 RCTs were included in meta-analysis, involving 1356 and 1365 patients in S-1 and non- S-1-based chemotherapy. Meta-analysis showed that S-1-based chemotherapy significantly improved progression-free survival (PFS) (HR 0.90, 95% CI: 0.84-0.97, P = 0.006). In subgroup analysis, there was statistically significant increase in PFS when S-1-based chemotherapy was compared to 5-FU-based (HR 0.92, 95% CI 0.84–1.00, P = 0.04) or capecitabine-based chemotherapy (HR 0.85, 95% CI 0.73–0.99, P = 0.04). The meta-analysis of overall survival (OS) (P = 0.36), overall response rate (ORR) (P = 0.90), disease control rate (DCR) (P = 0.13) showed no statistical significance between S-1-based and non- S-1-based chemotherapy. The statistically significant differences in the meta-analysis indicated less incidence of graded 3-4 leucopenia(OR = 0.30, 95% CI: 0.13-0.71, P = 0.006) and hand-foot syndrome (HFS)(OR = 0.24, 95% CI: 0.10-0.58, P = 0.001) in the S-1-based chemotherapy, and there was no statistically significant difference in the incidence of grade 3-4 diarrhea, nausea/vomit, fatigue, stomatitis, sensory neuropathy, gastrointestinal perforation between two groups.
Conclusions
S-1-based chemotherapy had longer PFS and better safety than 5-FU-based or capecitabine-based chemotherapy, and S-1-based chemotherapy in mono or combined therapy was an attractive alternative to standard first-line regimen for patients of CRC, but further investigations in larger populations would be needed to confirm it.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Zhan Wang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
750 - HER2 positive rates in Invasive Lobular Breast Carcinoma : A study amongst 1,095 consecutive Asian patients
Presenter: Ga Jing Kee
Session: Poster display - Cocktail
Resources:
Abstract
1417 - CanAssist-breast -an immunohistochemistry based test for risk of recurrence prediction for early stage breast cancer patients: a cost-effective and accurate solution for Asia
Presenter: Manjiri Bakre
Session: Poster display - Cocktail
Resources:
Abstract
1468 - Topical silymarin administration for prevention of radiodermatitis in breast cancer patients: a randomized, double-blind, placebo-controlled clinical trial
Presenter: Sepideh Elyasi
Session: Poster display - Cocktail
Resources:
Abstract
873 - Comparison of interstitial brachytherapy with volumetric modulated arc therapy for tumour bed boost following breast conservative surgery
Presenter: Kannan Periasamy
Session: Poster display - Cocktail
Resources:
Abstract
1140 - Triple Negative Breast Cancer and Platinum-based Systemic Treatment: Meta-analysis and Systematic Review
Presenter: Jessa Gilda Pandy
Session: Poster display - Cocktail
Resources:
Abstract
168 - Longitudinal study on incidences of obesity and weight changes in Chinese patients with early-stage breast cancer
Presenter: Winnie Yeo
Session: Poster display - Cocktail
Resources:
Abstract
311 - Effect of combined CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome in breast cancer indicates endogenous and exogenous interplay
Presenter: Hanjing Xie
Session: Poster display - Cocktail
Resources:
Abstract
669 - A novel nipple aleolar complex involvement predictive index (NACPI) for indicating nipple sparing mastectomy in breast cancer
Presenter: Hirohito Seki
Session: Poster display - Cocktail
Resources:
Abstract
938 - Multicenter Trial for Safety and Toxicity of Nanoxel®M in Breast Cancer
Presenter: Tae Hyun Kim
Session: Poster display - Cocktail
Resources:
Abstract
1129 - Implication of PET-CT to improve negative predictive value for axillary lymph node metastasis in early breast cancer
Presenter: Oyeon Cho
Session: Poster display - Cocktail
Resources:
Abstract